- •Limited data available on the effect of prior antiplatelet use on safety and functional outcome of stroke patients who receive IV thrombolysis.
- •Our data is from a large volume comprehensive stroke center in the United States.
- •No significant association shown between the risk of symptomatic ICH and good functional outcome after IV thrombolysis for stroke patients on antiplatelet therapy (dual or single) in comparison with antiplatelet naïve patients.
To study the effects of pretreatment with Antiplatelet (AP) before IV thrombolysis (IVT) on the rate of symptomatic intracranial hemorrhage (sICH) and functional outcome in patients with Acute Ischemic stroke (AIS).
In this retrospective study, the medical records and cerebrovascular images of all the patients who received IVT for AIS in our center in a 9.6-year period were reviewed. Patients who took at least one dose of any APs in the last 24 h prior to IVT were identified. They were categorized according to the type of AP, single versus dual AP therapy (DAPT), and dose of AP. Rate of sICH and functional outcome at discharge were compared between the AP users and non-users.
A total of 834 patients received IVT for AIS in our center during a 9.6- year period. Multivariate models were adjusted for age, NIHSS on admission, history of atrial fibrillation, history of hypertension, INR on admission, history of stroke and diabetes mellitus. In multivariate regression analyses and after adjusting for the variables mentioned above, the use of any AP was not associated with an increased rate of sICH (OR = 1.28 [0.70–2.34], p = 0.425). Furthermore, the use of DAPT did not significantly increase the rate of sICH in multivariate regression analyses. (OR = 0.663 [0.15–2.84], p = 0.580). The patients on any AP had a lower chance of having good functional outcome in univariate analysis (OR = 0.735 [0.552–0.979], p = 0.035). However, when adjusted for age, baseline NIHSS, history of diabetes, hypertension and prior stroke, AP use was not associated with a decreased chance of having a good functional outcome at discharge. (OR = 0.967 [0.690–1.357], p = 0.848). In addition, no significant difference was noted in the rate of good functional outcome between patients on DAPT and no AP users in multivariate regression analyses. (OR = 1.174 [0.612–2.253], p = 0.629).
Our study did not show any significant association between the risk of sICH and good functional outcome after IVT for AIS patients on AP therapy (dual or single) in comparison with AP naïve patients.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of the Neurological Sciences
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Tissue plasminogen activator for acute ischemic stroke.N. Engl. J. Med. 1995; 333: 1581-1587
- Is acute reperfusion therapy safe in acute ischemic stroke patients who harbor unruptured intracranial aneurysm?.Int. J. Stroke. 2015; : 113-118
- Safety of intravenous thrombolysis for acute ischemic stroke in patients with preexisting intracranial neoplasms: a case series.Int. J. Stroke. 2015; 10 (E29-30)
- Delays in door-to-needle time for acute ischemic stroke in the emergency department: A comprehensive stroke center experience.J. Neurol. Sci. 2017; 376: 102-105
- Successful intravenous thrombolysis for acute stroke caused by polycythemia vera.Arch. Neurosci. 2017; 4e62181
- Safety of intravenous thrombolysis among patients taking direct oral anticoagulants: a systematic review and meta-analysis.Stroke. 2020; 51: 533-541
- Intravenous thrombolysis for acute ischemic stroke in patients with thrombocytopenia.J. Stroke Cerebrovasc. Dis. 2017; 26: 1414-1418
- Rate, clinical features, safety profile and outcome of intravenous thrombolysis for acute ischemic stroke in patients with negative brain Imaging.J. Neurol. Res. 2020; 10: 144-145
- Prior asymptomatic parenchymal hemorrhage does not increase the risk for intracranial hemorrhage after intravenous thrombolysis.Cerebrovasc. Dis. 2015; 40: 201-204
- Recurrent ischemic stroke can happen in stroke patients very early after intravenous thrombolysis.J. Neurol. Sci. 2015; 358: 496-497
- Acute pancreatitis in the setting of acute Ischemic stroke.Arch. Neurosci. 2017; 4e42957
- Does body mass index impact the outcome of stroke patients who received intravenous thrombolysis?.Cerebrovasc. Dis. 2021 Jan; 8: 1-6
- Laboratory factors associated with symptomatic hemorrhagic conversion of acute stroke after systemic thrombolysis.J. Neurol. Sci. 2020 Dec 9; 420: 117265
- Statins use and outcome of acute Ischemic stroke patients after systemic thrombolysis.Cerebrovasc. Dis. 2020; 49: 503-508
- Safety of intravenous thrombolysis for acute Ischemic stroke in patients taking warfarin with subtherapeutic INR.J. Stroke Cerebrovasc. Dis. 2021; 30: 105678
- Strokes occurring in the hospital: Symptom recognition and eligibility for treatment in the intensive care units versus hospital wards.Brain Circ. 2020; 6: 196-199
- Dual antiplatelet therapy pretreatment in IV thrombolysis for acute ischemic stroke.Neurology. 2018; 91: e1067-e1076
- Safety and efficacy of dual antiplatelet pretreatment in patients with ischemic stroke treated with IV thrombolysis: A systematic review and meta-analysis.Neurology. 2020; 94: e657-e666
- Safety of intravenous thrombolysis for acute ischemic stroke in patientsreceiving antiplatelet therapy at stroke onset.Stroke. 2010; 41: 288-294
- Prior antiplatelet agent use and outcomes after intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: a meta-analysis of cohort studies and randomized controlled trials.Int. J. Stroke. 2015; 10: 317-323
- Interobserver agreement for the assessment of handicap in stroke patients.Stroke. 1988; 19: 604-607
- Markedly reduced apparent blood volume on bolus contrast magnetic resonance imaging as a predictor of hemorrhage after thrombolytic therapy for acute ischemic stroke.Stroke. 2005; 36: 746-750
- Antiplatelet therapy and the risk of intracranial hemorrhage after intravenous tissue plasminogen activator therapy for acute ischemic stroke.Arch. Neurol. 2008; 65: 575-576
- Low- versus standard-dose alteplase in patients on prior antiplatelet therapy: the ENCHANTED trial (enhanced control of hypertension and thrombolysis stroke study).Stroke. 2017; 48: 1877-1883
- Early administration of Aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial.Lancet. 2012; 380: 731-737
- Intravenous thrombolysis for acute Ischemic stroke in patients receiving antiplatelet therapy: a systematic review and meta-analysis of 19 studies.J. Am. Heart Assoc. 2016; 5e003242
- Risks and benefits associated with prestroke antiplatelet therapy among patients with acute Ischemic stroke treated with intravenous tissue plasminogen activator.JAMA Neurol. 2016; 73: 50-59
- Prior dual antiplatelet therapy and thrombolysis in acute stroke.Ann. Neurol. 2020; 88: 857-859
- Discharge destination as a surrogate for Modified Rankin Scale defined outcomes at 3- and 12-months poststroke among stroke survivors.Arch. Phys. Med. Rehabil. 2012; 93 (1408-1413.e1)
- Guidelines for the early management of patients with acute Ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2018; 49 (2018): e46-e110
Published online: April 15, 2021
Accepted: April 12, 2021
Received in revised form: March 18, 2021
Received: November 13, 2020
© 2021 Elsevier B.V. All rights reserved.